483
Merck & CompanyMerck & Company – FDA 483, Jan 20, 2021
Record Details
An FDA inspection of Merck & Company in Rahway, NJ, identified a failure to ensure proper monitoring of a clinical study. Specifically, the firm did not submit monitoring follow-up letters with visit reports within the required timeframe as stipulated in their own Clinical Monitoring Plan. This indicates a procedural lapse in clinical trial oversight.
View Company Profile
ID · 8fe7da63-81b9-4bc2-b4b0-bdfc3a1fbe5c
Other documents for Merck & Company
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.